. Author manuscript; available in PMC: 2013 Jul 18.

Published in final edited form as: Expert Rev Anticancer Ther. 2012 Sep;12(9):1149–1159. doi: 10.1586/era.12.91

Table 1.

ErbB/HER family members in clinical trials for head and neck squamous cell carcinoma.

Agent	Target (s)	Phase of development in HNSCC^†
Monoclonal antibodies
Cetuximab	EGFR	Approved
Panitumumab	EGFR	III
Zalutumumab	EGFR	III
Nimotuzumab	EGFR	III^‡
Tyrosine kinase inhibitors
Lapatinib (reversible)	EGFR and HER2	III
Afatinib (irreversible)	EGFR, HER2 and HER4	III
Erlotinib (reversible)	EGFR	II^§
Dacomitinib (irreversible)	EGFR, HER2 and HER4	II

Includes agents with at least one clinical trial in HNSCC indexed on [102] as of April 2012.

^†

Highest phase for which at least one trial (monotherapy or with chemotherapy and/or radiation irrespective of treatment setting [neoadjuvant, adjuvant and primary treatment]) was recruiting or active but not recruiting per [102] as of April 2012.

^‡

Approved for treating HNSCC in some non-USA countries.

^§

Phase III trials had been initiated but were terminated early for low accrual, as per [102] summaries.

EGFR: EGF receptor; HER: Human EGFR; HNSCC: Head and neck squamous cell carcinoma.